Chih‐Hsi S. Kuo

2.6k citations

72 papers · 954 indexed · h-index 16

Pulmonary and Respiratory Medicine top 5%
Oncology top 10%
Physiology top 10%
Immunology
Molecular Biology

Co-authors: Cheng‐Ta Yang Ping‐Chih Hsu Yike Guo Yi‐Lung Chen Kian Fan Chung Ian M. Adcock Stelios Pavlidis Yueh‐Fu Fang
Topics: Lung Cancer Treatments and Mutations (45 papers)Colorectal Cancer Treatments and Studies (22 papers)Lung Cancer Research Studies (18 papers)
Cited by: Pulmonary and Respiratory Medicine Oncology Physiology
Journals: Journal of Clinical Oncology Scientific Reports Clinical Cancer Research
Partner nations: Taiwan United Kingdom United States

In The Last Decade

Chih‐Hsi S. Kuo

68 papers receiving 944 citations

Peers

Countries citing papers authored by Chih‐Hsi S. Kuo

Since Specialization

Citations

This map shows the geographic impact of Chih‐Hsi S. Kuo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chih‐Hsi S. Kuo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chih‐Hsi S. Kuo more than expected).

Fields of papers citing papers by Chih‐Hsi S. Kuo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chih‐Hsi S. Kuo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chih‐Hsi S. Kuo. The network helps show where Chih‐Hsi S. Kuo may publish in the future.

Co-authorship network of co-authors of Chih‐Hsi S. Kuo

This figure shows the co-authorship network connecting the top 25 collaborators of Chih‐Hsi S. Kuo. A scholar is included among the top collaborators of Chih‐Hsi S. Kuo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chih‐Hsi S. Kuo. Chih‐Hsi S. Kuo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical outcome analysis of different first‑ and second‑generation EGFR‑tyrosine kinase inhibitors in untreated patients with EGFR‑mutated non‑small cell lung cancer with baseline brain metastasis 2025 ·Oncology Letters ·Chih‐Hung Hsu,Li‐Chung Chiu,(unknown),(unknown),Chih‐Hsi S. Kuo,(unknown),(unknown),Chin‐Chou Wang,Cheng‐Ta Yang,Ping‐Chih Hsu	1
2	Clinical impact of the rapid genomic screening platform for non-small cell lung cancer in Asia-Pacific (LC-SCRUM-AP). 2024 ·Journal of Clinical Oncology ·Shigeki Umemura,Chih‐Hsi S. Kuo,Virote Sriuranpong,Muthukkumaran Thiagarajan,Charuwan Akewanlop,(unknown),Yuji Shibata,(unknown),Tatsuya Ikeda,(unknown),(unknown),Christer Svedman,Takashi Seto,Hiroki Izumi,(unknown),Kōichi Goto	0
3	Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer 2024 ·Thoracic Cancer ·Li‐Chung Chiu,Ping‐Chih Hsu,Chin‐Chou Wang,(unknown),Chih‐Hsi S. Kuo,(unknown),(unknown),(unknown),Cheng‐Ta Yang	2
4	A Clinical Analysis of Anti-Programmed Death-Ligand 1 (PD-L1) Immune Checkpoint Inhibitor Treatments Combined with Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer 2024 ·Vaccines ·Ping‐Chih Hsu,(unknown),Chin‐Chou Wang,Li‐Chung Chiu,(unknown),(unknown),Chiao‐En Wu,Chih‐Hsi S. Kuo,(unknown),(unknown),Yu‐Ching Lin,Cheng‐Ta Yang,(unknown)	1
5	Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC 2023 ·Scientific Reports ·(unknown),(unknown),(unknown),Chi‐Hsien Huang,(unknown),Chin‐Chou Wang,(unknown),Fu‐Tsai Chung,Ping‐Chih Hsu,Yueh‐Fu Fang,Yike Guo,Chih‐Hsi S. Kuo,Cheng‐Ta Yang	8
6	Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR -Mutant and RET Fusion-Positive Lung Cancers 2023 ·Clinical Cancer Research ·Julia Rotow,Jyoti D. Patel,(unknown),Helena A. Yu,Mark M. Awad,Jonathan W. Goldman,Hovav Nechushtan,Matthias Scheffler,Chih‐Hsi S. Kuo,Senthil Rajappa,Guilherme Harada,(unknown),(unknown),(unknown),Rebecca Tupper,Geoffrey R. Oxnard,Jennifer Kherani,Alexander Drilon	26
7	Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan 2023 ·Targeted Oncology ·Ping‐Chih Hsu,(unknown),Li‐Chung Chiu,Chung-Shu Lee,(unknown),Chih‐Hsi S. Kuo,(unknown),(unknown),Shih‐Hong Li,(unknown),Cheng‐Ta Yang,Chin‐Chou Wang	15
8	Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations 2022 ·Therapeutic Advances in Respiratory Disease ·Ping‐Chih Hsu,John Wen‐Cheng Chang,(unknown),Chen‐Yang Huang,Cheng‐Ta Yang,Chih‐Hsi S. Kuo,Yueh‐Fu Fang,(unknown)	10
9	Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI 2022 ·Cancers ·John Wen‐Cheng Chang,Chen‐Yang Huang,Yueh‐Fu Fang,(unknown),Cheng‐Ta Yang,Chih‐Hsi S. Kuo,Ping‐Chih Hsu,(unknown)	11
10	Afatinib Treatment Alone or with Bevacizumab in a Real-World Cohort of Non-Small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Mutation 2022 ·Cancers ·Chih‐Hsi S. Kuo,(unknown),(unknown),Chi‐Hsien Huang,(unknown),(unknown),Chin‐Chou Wang,(unknown),Ping‐Chih Hsu,Yueh‐Fu Fang,Yike Guo,Cheng‐Ta Yang	7
11	Overall Survival Improvement in Patients with Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer and Bone Metastasis Treated with Denosumab 2022 ·Cancers ·(unknown),Chi‐Tsun Chiu,Chih‐Liang Wang,Tsung‐Ying Yang,Chien‐Ying Liu,Chih‐Teng Yu,(unknown),Chih‐Hsi S. Kuo,Chin‐Chou Wang,Muh‐Hwa Yang,Cheng‐Ta Yang	9
12	Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study 2022 ·Therapeutic Advances in Medical Oncology ·(unknown),Yu‐Ching Lin,Li‐Chung Chiu,(unknown),(unknown),(unknown),Shih‐Hong Li,Yueh‐Fu Fang,Chih‐Hung Chen,Chih‐Hsi S. Kuo,Chin‐Chou Wang,Cheng‐Ta Yang,Ping‐Chih Hsu	7
13	A retrospective study of alectinib versus ceritinib in patients with advanced non–small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed 2021 ·BMC Cancer ·Chih‐Hsi S. Kuo,(unknown),(unknown),Chin‐Chou Wang,John Wen‐Cheng Chang,Chien‐Ying Liu,Fu‐Tsai Chung,Yueh‐Fu Fang,Yike Guo,Cheng‐Ta Yang	5
14	Blood Cadmium Levels and Oxygen Desaturation during the 6-Minute Walk Test in Patients with Chronic Obstructive Pulmonary Disease 2021 ·Medicina ·Li‐Chung Chiu,Ping‐Chih Hsu,Tzung‐Hai Yen,Chih‐Hsi S. Kuo,Yueh‐Fu Fang,Yu‐Lun Lo,Shu‐Min Lin,Cheng‐Ta Yang,Chung-Shu Lee	3
15	First- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large, real-world cohort of patients with non-small cell lung cancer 2021 ·Therapeutic Advances in Medical Oncology ·(unknown),Chi‐Hsien Huang,(unknown),(unknown),(unknown),Chin‐Chou Wang,Chien‐Ying Liu,Fu‐Tsai Chung,Yueh‐Fu Fang,Yike Guo,Chih‐Hsi S. Kuo,Cheng‐Ta Yang	17
16	Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer 2020 ·Thoracic Cancer ·(unknown),(unknown),Chin‐Chou Wang,(unknown),(unknown),Chien‐Ying Liu,Chih‐Liang Wang,(unknown),Fu‐Tsai Chung,Ping‐Chih Hsu,Yike Guo,Chih‐Hsi S. Kuo,Cheng‐Ta Yang	28
17	Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non‐small cell lung cancer: Results of a single‐arm prospective cohort study 2019 ·Thoracic Cancer ·Ping‐Chih Hsu,(unknown),Chun‐Chieh Wang,Chen‐Te Wu,Yu‐Ching Lin,Chih‐Liang Wang,Ting‐Yu Lin,Shih‐Hong Li,Yichen Wu,Chih‐Hsi S. Kuo,Cheng‐Ta Yang,Chien‐Ying Liu,Chih‐Hung Chen	4
18	Prior EGFR-TKI Treatment in EGFR-Mutated NSCLC Affects the Allele Frequency Fraction of Acquired T790M and the Subsequent Efficacy of Osimertinib 2019 ·Targeted Oncology ·Chih‐Hsi S. Kuo,Chi‐Hsien Huang,Chien‐Ying Liu,Stelios Pavlidis,(unknown),Fu‐Tsai Chung,Ting‐Yu Lin,Chih‐Liang Wang,Yike Guo,Cheng‐Ta Yang	10
19	The Prevalence of PD-L1 Expression in Lung Cancer 2019 ·Yu‐Chen Chang,Ping‐Chih Hsu,(unknown),(unknown),Chih‐Hsi S. Kuo,(unknown),Chien‐Ying Liu	6
20	Impact of prolonged and early bevacizumab treatment on the overall survival of EGFR‐mutant and EGFR‐wild type nonsquamous non‐small cell lung cancer 2018 ·Thoracic Cancer ·Yu‐Chen Huang,(unknown),Chien‐Ying Liu,Stelios Pavlidis,Chih‐Liang Wang,(unknown),Fu‐Tsai Chung,Ting‐Yu Lin,(unknown),Kang‐Yun Lee,Yike Guo,Cheng‐Ta Yang,Chih‐Hsi S. Kuo	3

About Chih‐Hsi S. Kuo

Chih‐Hsi S. Kuo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Anesthesiology and Pain Medicine, having authored 72 papers that have together received 954 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (45 papers), Colorectal Cancer Treatments and Studies (22 papers) and Lung Cancer Research Studies (18 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (607 citations), Oncology (409 citations) and Physiology (263 citations). Chih‐Hsi S. Kuo has collaborated with scholars based in Taiwan, United Kingdom and United States. Frequent co-authors include Cheng‐Ta Yang, Ping‐Chih Hsu, Yike Guo, Yi‐Lung Chen, Kian Fan Chung, Ian M. Adcock, Stelios Pavlidis, Yueh‐Fu Fang, Peter J. Sterk and Ratko Djukanović. Their work appears in journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact